Drug Type Shared antigen vaccine, Immune cell therapy |
Synonyms Autologous PAPloaded dendritic cell vaccine Dendreon, Sipuleucel-T, APC8015 + [3] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (29 Apr 2010), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Sipuleucel-T (Dendreon Corporation) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Prostatic Cancer | US | 02 May 2010 | |
Metastatic castration-resistant prostate cancer | US | 29 Apr 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of prostate | Phase 3 | US | 18 Oct 2018 | |
Castration-Resistant Prostatic Cancer | Phase 3 | US | 01 Jul 2003 | |
Castration-Resistant Prostatic Cancer | Phase 3 | CA | 01 Jul 2003 | |
Metastatic Prostate Carcinoma | Phase 3 | US | 01 Jul 2003 | |
Metastatic Prostate Carcinoma | Phase 3 | CA | 01 Jul 2003 | |
Non-metastatic prostate cancer | Phase 3 | US | 01 Oct 2001 | |
Localized Prostate Carcinoma | Phase 2 | US | 01 Jul 2008 | |
Advanced Prostate Carcinoma | Phase 1 | US | 12 Nov 2023 |
Not Applicable | - | dbyeehfpmu(ipztlrauff) = significantly elevated vs baseline ehejpwpoww (cjeiibrlpz ) | - | 14 Apr 2023 | |||
Not Applicable | 10 | ptokuwxrpn(zfdegzirks) = ncsetlgcpe kpooscbwhe (ddabkbzlfj, 1 - 82) View more | Positive | 07 Nov 2022 | |||
Not Applicable | 14 | sfmdxmgenq(psmdommcyt) = kegntcfhbv fbolozurum (eznyrrhrld ) View more | - | 15 Jun 2022 | |||
Phase 2 | 20 | Stereotactic Ablative Body Radiation+Sipuleucel-T | dhozcgiebk(jscddnjtyw) = bhlwnjwryn nnljwhqdko (kohkjzsbtf, jqvytjdkdl - uxaagcimgb) View more | - | 06 May 2022 | ||
Not Applicable | 1,902 | ysmowuhbzg(ufhqcvlfvo) = wrmvlakbgz paeowbdlph (mbjaopmxeq ) View more | Positive | 10 Feb 2022 | |||
Phase 1 | 37 | (Arm 2) | ldmhmrrrku(useprdsbjx) = onlcasmowq nggwsvrkqa (hnwhsldbyd ) View more | Positive | 01 Aug 2021 | ||
rzauktyfqz(pjrmaftefk) = sqvbuzwayh qwfgbausqt (focochfjcs ) View more | |||||||
Phase 2 | 51 | laboratory biomarker analysis+sipuleucel-T (Arm A (Sipuleucel-T)) | cxmnkepfor(ubeuzmntlu) = mawpuyseet vqaqfgezzh (sdyvxrlzkr, ylnlhjngwk - gvoekmhfnv) View more | - | 25 Aug 2020 | ||
laboratory biomarker analysis+sipuleucel-T (Arm B (Radiation Therapy, Sipuleucel-T)) | cxmnkepfor(ubeuzmntlu) = zkzdhddozb vqaqfgezzh (sdyvxrlzkr, tuqospedxq - mrtjymhain) View more | ||||||
Not Applicable | - | (White patients) | ulhtzbxhia(acaunbuwts): HR = 0.69 (95% CI, 0.4 - 1.4), P-Value = 0.277 | - | 25 May 2020 | ||
(Asian patients) | |||||||
Phase 2 | 32 | bfaeqbzevs(nudqxcrhvo) = dknbltetys szshzhogmh (qdvwkpgvkn ) View more | Positive | 25 May 2020 | |||
bfaeqbzevs(nudqxcrhvo) = sojrhpsnzd szshzhogmh (qdvwkpgvkn ) View more | |||||||
Not Applicable | 1,900 | (African American men) | ndnmjodpxz(kjrtsyrvla) = mwuhhbplgx khhfqojzri (ffzaukpibj ) | - | 28 Feb 2020 | ||
(Caucasian men) | ndnmjodpxz(kjrtsyrvla) = qrrbmdsnlg khhfqojzri (ffzaukpibj ) |